Table 2

Examples of non-inferiority trials of reduced intensity therapies included in the analysis. See online appendix 1 for a full bibliography of all 31 trials

First authorDiseaseExperimental therapyActive controlOutcome
Anderson29 Ischaemic strokeLow-dose alteplaseStandard dose alteplaseDeath or disability at 90 days
Johnson11 Hodgkin’s lymphomaABVABVD3-year progression free survival
Sherman30 Hepatitis C virus infection24 weeks telaprevir48 weeks telaprevirSustained virological response
Pritchard-Jones31 Wilms' tumourOmission of doxorubicinInclusion of doxorubicinEvent-free survival 2 years after diagnosis
Bernard32 Pyogenic vertebral osteomyelitis6 weeks of antibiotics12 weeks of antibioticsClinical cure rate
Vaidya33 Breast cancerTargeted radiotherapyWhole breast radiotherapyLocal recurrence rate
van Herwaarden34 Rheumatoid arthritisWithdrawal of adalimumab or etanerceptContinuation of adalimumab or etanerceptRate of major flare at 18 months
Feres35 Coronary stenting3 months antiplatelet therapy12 months antiplatelet therapyNet adverse clinical and cerebral events
Rahman36 Malignant pleural effusions12 French tube24 French tubePleurodesis efficacy
Barone37 Genital fistula7 days postoperative bladder catheterisation14 days postoperative bladder catheterisationRepair breakdown rate
  • ABV, Adriamycin, bleomycin, vinblastine; ABVD, Adriamycin, bleomycin, vinblastine, dacarbazine.